Compare Prudential PLC (PUK) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs Twist Bioscience Corp — how do they compare? Prudential PLC trades at $23.88 (market cap $28.84B), while Twist Bioscience Corp trades at $163.25 (market cap $10.08B). The key difference: Prudential PLC is far larger — about 2.9× Twist Bioscience Corp's market cap, and Prudential PLC pays a 2.33% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and Twist Bioscience Corp for 27 Days on average.
| PUK | TWST | |
|---|---|---|
Market Cap | $28.84B | $10.08B |
Volume | 3,531,298 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $33.61 | $205.00 |
52-Week Low | $23.54 | $25.45 |
Typical Hold Time | 119 Days | 27 Days |
Enterprise Value | $28.38B | $10.01B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUK trades at $23.54, down 4.31% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent news highlights strategic moves including the sale of its Alexforbes stake and a rebranding of its wealth management unit. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook is mixed: solid fundamentals and growth initiatives support upside, but technical weakness and earnings volatility pose risks. Investment opportunity lies in the attractive valuation (P/E 8.4) and strategic focus, countered by bearish momentum and competitive pressures in insurance markets.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
